Rationale: Vascular remodeling in pulmonary arterial hypertension (PAH) results from smooth muscle cell hypertrophy and proliferation of vascular cells. Loss of BMPR-II (bone morphogenetic protein receptor 2) signaling and increased signaling via TGF-b (transforming growth factor b) and its downstream mediators SMAD (small body size [a C. elegans protein] mothers against decapentaplegic [a Drosophila protein family])-2/3 has been proposed to drive lung vascular remodeling; yet, proteomic analyses indicate a loss of SMAD3 in PAH.
Pulmonary arterial hypertension (PAH) is a rare but fatal disease, characterized by extensive remodeling of pulmonary arteries and muscularization of precapillary arterioles (1, 2) . Clinical and experimental data point toward a central role for TGF-b (transforming growth factor b) signaling in PAH, in that a series of mutations in this pathway have been associated with PAH (3) (4) (5) (6) (7) (8) (9) (10) and in that TGF-b expression is increased in pulmonary arteries and lungs of patients with PAH and respective animal models (11, 12) .
By signaling through its canonical pathway, TGF-b, activates receptorinduced SMADs (small body size [a C. elegans protein] mothers against decapentaplegic [a Drosophila protein family]) (R-SMADs, namely SMAD2 and SMAD3), which in turn promote gene expression involved in hypertrophy and fibrosis (13) . On a simplistic level, the documented elevated plasma levels for TGF-b in PAH (14, 15) would therefore lead one to expect that SMADs downstream of TGF-b may play a crucial role in the pathogenesis of experimental or clinical PAH. Counterintuitively, however, a significant decrease in pulmonary SMAD3 expression was detected in PAH animal models as well as in patients with PAH (11, 12) , in line with the fact that prolonged exposure to TGF-b can result in loss of SMAD3 (16) . Hence, PAH may actually be associated with a decrease in the activity of the canonical TGF-b pathway.
Although systemic cardiovascular diseases are commonly associated with a switch from a differentiated vascular smooth muscle cell phenotype with high expression of contractile proteins and low migration/proliferation abilities to a proliferative dedifferentiated phenotype with weak contractile protein expression and increased migration, proliferation, and resistance to apoptosis (17) (18) (19) (20) , vascular remodeling in PAH is characterized by both dedifferentiation and increased smooth muscle cell (SMC) proliferation (hyperplasia), as well as an overall increase in smooth muscle protein (e.g., SMA [a-smooth muscle actin]) expression characteristic of SMC hypertrophy (21) . As contractile and proliferative SMC phenotypes are commonly considered mutually exclusive, the seeming contradiction of the parallel induction of both human pulmonary artery smooth muscle cell (huPASMC) hyperplasia and hypertrophy in PAH disease has so far remained enigmatic. MRTF (myocardin-related transcription factor) is a Rho GTPaseresponsive, actin-regulated transcriptional coactivator of SRF (serum response factor), a master regulator of expression of muscle protein, including SMA, that plays a crucial role in both maintenance of normal SMC homeostasis (22, 23) and pathological vascular remodeling (24) . Although the central role of MRTF in SMC hypertrophy renders it an attractive candidate contributor to vascular remodeling, MRTF dysregulation in PAH and its underlying mechanism have not yet been addressed.
MRTF dysregulation may be intrinsically linked to altered TGF-b signaling, as suggested by our previous studies in kidney epithelial cells, where we found SMAD3 capable of binding MRTF, thereby inhibiting MRTF-driven activation of the SMA promoter (25) (26) (27) (28) . Because SMAD3 may concomitantly exert antiproliferative effects (29, 30) , a general loss of SMAD3 in PAH may drive both SMA expression via disinhibition of MRTF and huPASMC proliferation, and thus might explain the parallel existence of a hypertrophic and proliferative huPASMC phenotype in PAH (31) (32) (33) . To test this notion, we analyzed SMAD3 expression levels in clinical samples and preclinical models of PAH and explored the protein-protein interaction between SMAD3 and MRTF and their functional roles in huPASMC and human pulmonary artery endothelial cells (huPAECs) relevant to the development and progression of PAH both in vitro and in vivo.
Methods
For full experimental details, including information on proliferation and migration assays, protein isolation and Western blotting, RNA isolation and real-time polymerase chain reaction, cell transfection, coimmunoprecipitation, animal models of pulmonary hypertension, and assessment of their endpoints please see the online supplement.
Human Tissue Samples
Human lung tissues were obtained from seven control subjects who died unexpectedly from nonpulmonary causes and seven patients with PAH for whom clinical characteristics are given in Table E1 in the online supplement. Samples were collected under the ethic protocol #20773 at Laval University and used following current recommendations (34) .
Cells
huPASMC and huPAEC were purchased from Lonza or PromoCell or isolated from downsized nontumorous nontransplanted donor lungs (EK 976/2010, Medical University of Vienna) and cultured in Smooth Muscle or Endothelial Cell Growth Medium 2, respectively (PromoCell). Murine PASMCs were obtained from BMPR2 1/R899X mice, which carry a mutated allele of the BMPR2 gene, and corresponding wild-type mice as described (35) .
Transfection
Predesigned, commercially available siRNA sequences directed against human SMAD3 and BMPR2 were purchased (Dharmacon Thermo Scientific). For nonspecific gene inhibition of the siRNAs used in this study, a universal negativecontrol siRNA sequence was used (Dharmacon Thermo Scientific F43 F46  M52  Sex/age   SMAD3   SMA   GAPDH   M52  F59 F53  F68 F72 M65 M77  F48 F47  F54 F54 CTL PAH CTL PAH CTL PAH CTL PAH CTL PAH CTL PAH Figure 1 . SMAD3 protein expression is decreased and SMA (smooth muscle actin) and TGF-b (transforming growth factor b) protein expression are increased in clinical samples and preclinical models of pulmonary arterial hypertension (PAH). Representative Western blots (A, D, and I) and corresponding densitometric quantification (B, C, E-G, and J-L) show SMAD3 and SMA expression in (A-C) total lung lysates of seven patients with PAH as compared with healthy sex-and age-matched control subjects (CTL; n = 7) and SMAD3, SMA, and TGF-b expression in rat pulmonary arteries after (D-G) 3 weeks of monocrotaline (MCT) treatment relative to untreated control subjects (n = 8 each), or (I-L) after Sugen/hypoxia (Su/hyp) relative to untreated control subjects (n = 4 each used. For MRTF overexpression, a FLAGtagged MRTF construct was used. Cells were transfected with 100 nmol/L siRNA or 0.5 to 2 mg plasmid for 8 hours.
Pulmonary Hypertension Models
The study was approved by the animal care and use committee of St. Michael's Hospital, and experiments were performed in accordance with the Guide for the Care and 
Statistical Analysis
All data are given as means 6 SEM. Student t test (two-tailed) was used to compare two groups. Where appropriate, a two-way analysis of variance was applied with Tukey post hoc test. P values , 0.05 were considered statistically significant.
Results

Smad3 Is Downregulated in Clinical and Preclinical PAH Samples
Total SMAD3 protein levels were significantly decreased in lung lysates from seven patients with PAH as compared with healthy control subjects, whereas SMA expression was concomitantly elevated ( Figures 1A-1C ). Reduced SMAD3 staining in the intima and media of pulmonary arteries was also evident by immunohistochemistry in patients with PAH as compared with donor lungs ( Figure  E1 ). Similar downregulation of SMAD3 was detected in pulmonary arteries of two animal models of PAH, the MCT ( Figures  1D and 1E ) and the Sugen/hypoxia rat model ( Figures 1I and 1J ), whereas TGF-b and smooth muscle actin expression were significantly upregulated in either model ( Figures 1D, 1F , 1G, 1I, 1K, and 1L). RVSP data for both PAH models are given in Figures 1H and 1M . To test whether chronic upregulation of TGF-b in PAH is sufficient to explain this loss in SMAD3, we probed for the effects of TGF-b on SMAD3 expression in vitro. Although short-term exposure to TGF-b for 24 hours did not alter SMAD3 expression (data not shown), 72-hour treatment with 5 ng/ml TGF-b downregulated total SMAD3 levels in huPASMCs at both the protein and mRNA levels (Figures 2A-2C ). Increasing TGF-b to 10 ng/ml caused no further drop in SMAD3 levels; therefore, all subsequent experiments were performed at 5 ng/ml. Decreased SMAD3 protein levels were similarly detectable in huPAECs after 72 hours of exposure to 5 or 10 ng/ml TGF-b ( Figures 2D and 2E ). Likewise, hypoxia (1% O 2 ) as a trigger of pulmonary hypertension caused a significant drop in SMAD3 in huPASMC at the protein ( Figures 2F and 2G ) and mRNA level ( Figure 2H ) as well as in huPAECs ( Figures  2I and 2J ). Treatment with IL-6 or plateletderived growth factor previously implicated in PAH pathogenesis did not, however, reduce SMAD3 expression in huPASMCs or huPAECs, suggesting that loss of SMAD3 expression is not a universal response to all PAH-related stimuli ( Figure E2 ).
SMAD3 Downregulation Increases Proliferation and Migration
To test for functional consequences of SMAD3 loss, we silenced SMAD3 in huPASMCs by siRNA ( Figures 3A and 3B ) and assessed fetal calf serum (FCS)-induced proliferation in three independent assays. SMAD3-silenced huPASMCs exhibited (1) higher protein levels for proliferating cell nuclear antigen (PCNA) ( Figures 3A and 3C ), (2) increased staining for nuclear Ki-67 ( Figures 3D  and 3E ), and (3) higher bromodeoxyuridine (BrdU) levels ( Figure 3F ) as compared with control siRNA. A similar increase in FCS-induced proliferation was detectable as higher PCNA levels in SMAD3-silenced huPAECs relative to internal control ( Figure 3G) . A graph of group data normalized toward control siRNA is shown in Figure E6B . Downregulation of SMAD3 also stimulated huPASMC ( Figure 3H ) and huPAEC migration ( Figure 3I ) toward an FCS gradient. Thus, downregulation of SMAD3 is sufficient to replicate two major features of PAH: enhanced proliferation and migration of huPASMCs and huPAECs.
SMAD3 Downregulation Triggers Smooth Muscle Cell Hypertrophy
To test whether SMAD3 loss also triggers huPASMC hypertrophy, we assessed the effect of TGF-b treatment on the expression of SMA, a differentiation and hypertrophy marker in SMCs (37, 38) , and on the ratio of total protein to DNA content. TGF-b increased SMA expression and protein/DNA ratio in a time-dependent manner, which was associated with a concomitant decrease in SMAD3 levels ( Figures 4A-4C and 4E ). In line with a direct link between SMAD3 loss and SMC hypertrophy, SMAD3 protein expression correlated inversely with both SMA expression ( Figure 4D ) and protein/DNA ratio ( Figure 4F ). Consolidating the notion that loss of SMAD3 directly contributes to increased SMA expression, we next showed that SMAD3 silencing before TGF-b treatment augmented SMA expression in huPASMCs 24 hours after TGF-b ( Figures 4G and 4H ), whereas 72 hours after TGF-b no significant difference was observed between SMAD3-silenced and control siRNA-transfected cells ( Figures 4G and 4I ). This observation is in accord with the fact that by 72 hours, TGF-b treatment per se caused a drop in SMAD3 ( Figure 4A ), thus minimizing the effect of additional SMAD3 silencing ( Figure 4G ). Taken together, these experiments substantiate that TGFb-induced loss of SMAD3 promotes myogenic (hypertrophic) responses in SMC.
SMAD3-MRTF Interaction Is Decreased by TGF-b Treatment
In kidney tubular cells, we showed that SMAD3 interacts with MRTF (26), thereby inhibiting its effect on the SMA promoter (25) . To test for a similar scenario in PAH, where TGF-b-dependent loss of SMAD3 may accordingly potentiate SMA expression via enhanced MRTF signaling, we probed for SMAD3-MRTF interaction by coimmunoprecipitation. At baseline, MRTF pulled down substantial amounts of SMAD3, verifying the interaction of these proteins in resting huPASMC. TGF-b treatment for 72 hours reduced the level of MRTFassociated SMAD3 ( Figure 5A ). This effect is likely attributable to the comparable reduction in total SMAD3 after TGF-b, as evident in the coimmunoprecipitation input ( Figure 5B ), rather than a reduced affinity between the two proteins. Interaction between SMAD3 and MRTF was similarly reduced in pulmonary arteries of MCT-( Figure 5C ) or Sugen/hypoxia-( Figure 5D ) treated rats, a finding that is in line with MRTF disinhibition in PAH.
To probe whether loss of SMAD3 may indeed prime cells for enhanced MRTF activity, we treated huPASMCs with sphingosine-1-phosphate (S1P), a trigger of MRTF nuclear translocation and activation (39, 40) . In huPASMCs treated with control siRNA, S1P induced SMA expression in an MRTFdependent manner, as this effect was blocked by the MRTF inhibitor CCG1423 ( Figure 6A ). The latter effect was not attributable to induction of apoptosis by CCG1423, which could be effectively ruled out for both cell types ( Figures E3 and E4) . SMAD3 silencing amplified S1P-induced SMA expression, which was again sensitive to MRTF inhibition consistent with an intensified MRTF-dependent signaling after SMAD3 loss (Figures 6A and 6B) . Next, Figure E6A in the online supplement) or Sugen-hypoxia (Su/hyp)-treated rats and corresponding control rats (CTL; n = 4-5 independent experiments each) were immunoprecipitated with an MRTF antibody and immunoblotted for MRTF and SMAD3. Densitometric quantification demonstrates reduced Co-IP of SMAD3 with MRTF in experimental models of pulmonary arterial hypertension. *P , 0.05 versus CTL. t test was applied. Readers may view the uncut gel for A in the online supplement. Error bars show SEM.
we expressed the MRTF/SRF-sensitive luciferase reporter 3DA in huPASMCs and showed that SMAD3 overexpression attenuated reporter activation in response to either TGF-b stimulation ( Figure 6E ) or MRTF overexpression ( Figure 6F ), respectively, thus further validating the negative regulation of MRTFdependent transcriptional activity by SMAD3. SMAD3 knock-down also enhanced FCS-induced proliferation in huPASMCs as assessed by BrdU assay, yet this effect was not normalized by CCG1423 ( Figure 6C ). Similar results were obtained in huPAECs ( Figure 6D Figure 6 . Loss of SMAD3 primes for enhanced MRTF (myocardin-related transcription factor) activity. (A and B) Representative Western blots of SMA (smooth muscle actin) and SMAD3 (A) and corresponding densitometric quantification of SMA (B) levels (n = 5 independent experiments each) show increased expression of SMA after MRTF activation by sphingosine-1-phosphate (S1P; 1 mmol/L) in human pulmonary artery smooth muscle cells (huPASMCs) treated with SMAD3-specific (siSMAD3) relative to control (siCTL) siRNA that is sensitive to MRTF inhibition by CCG1423 (5 mmol/L). *P , 0.05 versus siCTL and S1P; # P , 0.05 versus siSMAD3 and S1P. (C and D) Quantitative measurement of bromodeoxyuridine (BrdU) incorporation into huPASMCs (C) or human pulmonary artery endothelial cells (huPAECs; D) shows increased proliferation in response to fetal calf serum (FCS; 5%) as compared with vehicle in both siCTL-and siSMAD3-treated huPASMCs or huPAECs and increased BrdU incorporation in siSMAD3 as compared with siCTL-treated, FCS-stimulated huPASMCs or huPAECs that is, however, not reversed by the MRTF inhibitor CCG1423 (n . 3 independent experiments each). *P , 0.05 versus siCTL; # P , 0.05 versus siCTL and CCG1423;
x P , 0.05 versus siSMAD3; $ P , 0.05 versus siSMAD3 and CCG1423. Two-way ANOVA was applied with Tukey post hoc test. (E-G) Group data show luciferase reporter activity of the MRTF/SRF (serum response factor)-sensitive promoter 3DA in TGF-b (transforming growth factor b)-treated huPASMCs overexpressing an empty-GFP or SMAD3-GFP plasmid (E; n = 3 each) or huPASMCs coexpressing MRTF-FLAG with an empty-GFP or SMAD3-GFP overexpressing plasmid (F, n = 3). *P , 0.05 versus CTL. t test was applied. (G) MRTF-FLAG overexpressing huPASMCs silenced either with control or SMAD3 siRNA (n = 3). *P , 0.05 versus siCTL; # P , 0.05 versus siSMAD3. Two-way ANOVA was applied with Tukey post hoc test. Error bars show SEM. GFP = green fluorescent protein.
indicating that MRTF disinhibition contributes to hypertrophic yet not hyperplastic responses to loss of SMAD3 in lung vascular cells.
MRTF Inhibition Attenuates Pulmonary Hypertension and Vascular Remodeling in Rats
On the basis of our findings that 1) SMAD3 levels are decreased in clinical and preclinical PAH, and 2) loss of SMAD3 drives MRTF-dependent SMA expression, we hypothesized that pharmacological inhibition of MRTF may alleviate vascular remodeling in experimental PAH. To address this question, PAH was induced by Sugen/hypoxia, and rats were treated either in a prophylactic approach from Day 0 or in a therapeutic approach from Day 21 after SU5416 injection with daily injections of two different doses of CCG1423 or vehicle. As compared with untreated Sugen/hypoxia animals, CCG1423-treated rats showed reduced lung vascular remodeling ( Figures  7A and 7B ) and RVSP ( Figure 7C ). Echocardiographic parameters of right ventricular (RV) function were, however, only normalized by prophylactic treatment with high-dose CCG1423 but not with lowdose prophylaxis or either therapeutic treatment dose (Figures 7D and 7E ). This deviation of treatment effects on pulmonary hemodynamics and RV function may seem surprising; it is, however, in keeping with previous studies (41) , which identified impaired RV function as a prominent feature of the Sugen/hypoxia model that is not solely attributable to increased RV afterload but involves additional direct or indirect effects on the RV that may be less responsive to MRTF inhibition.
Loss of Functional BMPR-II Causes SMAD3 Loss, Which in Turn Drives PASMC Hypertrophy
Loss of functional BMPR-II signaling, either due to inherited or spontaneous BMPR2 gene mutations or to acquired loss of BMPR-II (42) , is a key contributing factor in the pathogenesis of PAH (43, 44) . To test for a link between impaired BMPR-II signaling and the SMAD3/MRTFdependent regulation of huPASMC hypertrophy, we made use of a transgenic mouse model that overexpresses a mutated form of BMPR2 (BMPR2 1/R899X ) and gradually develops PAH (45) . In whole lung lysates of BMPR2 1/R899X mice, total SMAD3 levels were markedly reduced as compared with control mice (Figure 8A ), indicating that loss of SMAD3 and subsequent MRTF disinhibition may contribute to lung vascular remodeling in cases of dysfunctional or deficient BMPR-II. In line with this view, PASMCs isolated from BMPR2 1/R899X mice had increased SMA and PCNA expression ( Figures 8B  and 8C ) as well as decreased total SMAD3 and BMPR-II protein levels.
To assess if impaired BMPR-II signaling may per se account for loss of SMAD3, we silenced BMPR2 in huPASMCs, which markedly decreased SMAD3 expression (Figures 9A-9C) . Consistent with the concept of MRTF disinhibition, SMA expression in response to S1P was enhanced in BMPR2-silenced cells, and this effect was prevented by CCG1423 ( Figures 9A and 9D) . Silencing of BMPR2 also increased TGF-b expression in huPASMCs, providing for a potential mechanistic link between BMPR-II and TGF-b (Figures 9E-9G) . Interestingly, MRTF inhibition also reduced the expression of both SMAD3 and BMPR-II in control siRNA-treated cells, a finding that not only corroborates the tight link of SMAD3 expression to the abundance of functional BMPR-II but also suggests that BMPR-II expression may be negatively regulated by MRTF in a homeostatic feedback loop. To link elevated SMA expression in response to S1P in BMPR2-silenced cells directly to the loss of SMAD3, we also transfected huPASMCs with a SMAD3-expressing plasmid to test whether reconstitution of SMAD3 may reverse the increase in SMA expression in S1P-stimulated, BMPR2-silenced cells. The latter notion was confirmed, in that BMPR2 silencing increased the formation of actin stress fibers and phalloidin staining in S1P-stimulated huPASMCs, yet this effect was antagonized and baseline phalloidin staining reduced in huPASMCoverexpressing SMAD3 (Figure 10 ).
Discussion
In the present study, we identified loss of SMAD3 as characteristic hallmark in different PAH-related scenarios and as central pathophysiological mechanism in lung vascular remodeling. Loss of SMAD3 drives PASMC hypertrophy via disinhibition of MRTF, while concomitantly stimulating PASMC and PAEC proliferation in an MRTF-independent manner. Importantly, these findings not only identify a novel shared and potentially targetable signaling pathway of vascular remodeling in PAH but also reconcile the seemingly contradictory parallel stimulation of both contractile and synthetic PASMC phenotypes in PAH. Induction of this pathway by BMPR-II dysfunction or deficiency provides for a novel explanation for the propensity of patients with spontaneous or inherited BMPR2 mutations to develop PAH, and-as we discuss laterresolves the conceptual dilemma of how functional BMPR-II deficiency may promote vascular remodeling given that BMP/BMPR-II signaling per se induces PASMC differentiation.
In line with previous reports indicating that SMAD3 may be downregulated in experimental PAH (11), we demonstrate here loss of SMAD3 in 1) human lung samples of patients with PAH, 2) pulmonary arteries from two preclinical models of PAH, 3) cultured huPASMCs stimulated by TGF-b or hypoxia, 4) a mouse model bearing a heterozygous knock-in allele of a human BMPR2 mutation, or 5) BMPR2-silenced huPASMCs. As such, loss of SMAD3 emerges as a common hallmark in different scale models of PAH disease. The mechanism of SMAD3 downregulation in PAH was not the focus of the present work but is potentially attributable to epigenetic regulation via miR-199a-5p, which is upregulated in rat models of PH (46) and negatively regulates SMAD3 expression in huPAECs and huPASMCs (46) .
The role of SMAD3 in cell signaling has classically been viewed primarily in terms of its function as transcriptional modulator that, on stimulation of the TGF-b type I receptor, becomes phosphorylated and, together with SMAD4, translocates to the nucleus, where it regulates the transcription of various TGF-b target genes by binding to the SMAD-binding element in their promoter region (47) . Here, we describe a fundamentally different role of SMAD3 in the regulation of TGF-b-induced gene expression, which is independent of its phosphorylation and nuclear translocation but relates to its overall downregulation in response to TGF-b or in pulmonary hypertension (25, 48, 49) . In huPASMCs and huPAECs, silencing of SMAD3 replicated key mechanisms of lung vascular remodeling in PAH, namely cell proliferation, migration, and-in the case of huPASMCs-hypertrophy. The parallel induction of both hyperplastic and hypertrophic responses by SMAD3 loss reconciles these seemingly opposing effects in a single molecule.
Induction of hypertrophy was attributable to liberation of the myogenic transcription factor MRTF from a tonic SMAD3-mediated inhibition. The relevance of SMAD3-MRTF interaction in vascular homeostasis, and the role of MRTF disinhibition after SMAD3 loss, was documented in a series of experiments, in that SMAD3 was shown to (14) . Loss of functional BMPR-II signaling extends, however, beyond BMPR2 mutations, as acquired loss of BMPR-II is a common trait in nongenetic forms of PAH in humans (42) and animal models (50) . The mechanism by which functionally relevant mutations or acquired loss of BMPR-II promote PAH has traditionally been attributed to a shift from a BMPR-II-dependent, SMAD1/5/8-mediated homeostatic vascular phenotype to a TGF-b-driven, SMAD2/3-mediated vascular remodeling (14) . In the present study, however, we show that SMAD3 is largely lost in PASMC carrying the BMPR2 mutation R899X, or after BMPR2 silencing, whereas loss of BMPR2 increased TGF-b expression. This finding is reconcilable with an initial predominance of TGFb/SMAD2/3 signaling in BMPR2-mutated or silenced cells, which in turn, however, results in a loss of SMAD3 (Figure 11 ). Hence, rather than promoting a long-term increase in SMAD2/3 signaling, functional loss of BMPR-II may promote PASMC hypertrophy via disinhibition of MRTF due to loss of SMAD3. Two findings confirm this notion: First, BMPR2 silencing increased S1P-induced SMA expression in huPASMCs in an MRTF-dependent manner. Second, overexpression of SMAD3 prevented the formation of actin stress fibers in huPASMCs in response to BMPR2 silencing. Although these findings establish loss of SMAD3 and subsequent MRTF disinhibition as important mechanisms driving PASMC hypertrophy after functional loss of BMPR-II signaling, the role of MRTF in BMPR-II signaling and (22, 23) , an effect that has been proposed to maintain the nonproliferative, differentiated PASMC phenotype in the healthy pulmonary vasculature (22) . Conversely, we demonstrate here an important role for MRTF signaling in PASMC hypertrophy and PAH development. Thus, MRTF's regulation differs under healthy (BMPR dominated) and pathological (TGF-b dominated) conditions. In the former case, MRTF is temporarily activated by BMPR-II and contributes to the maintenance of the contractile phenotype. In the latter case, MRTF acts on the background of SMAD3 loss (i.e., in the absence of its tonic inhibitor). This results in prolonged (dysregulated) MRTF activation, provoking a hypertrophic response that coincides with hyperproliferation as an independent consequence of SMAD3 loss. Thus, instead of the normal time segregation between contractile or synthetic responses, PAH is characterized by parallel existence of both. Figure 11 . Schematic of proposed signaling pathway. Short-term and long-term (chronic) effects of TGF-b (transforming growth factor b) stimulation on pulmonary artery smooth muscle cells. Initially, TGF-b signaling via the classic SMAD2/3 signaling axis predominates, resulting in expression of SMAD3-dependent target genes but antagonizing TGF-b-induced MRTF (myocardin-related transcription factor) activation by SMAD3-MRTF interaction. Chronic TGF-b stimulation, however, leads to downregulation of SMAD3 (red dashed line) and, therefore, reduced expression of SMAD3-dependent target genes. Functional loss of BMPR-II (bone morphogenetic protein receptor 2) receptor signaling due to BMPR2 mutations or receptor downregulation, respectively, replicates this effect, presumably in part by increasing TGF-b expression. Loss of SMAD3 then stimulates cell proliferation and migration in an MRTF-independent manner and concomitantly disinhibits MRTF (indicated by red cross), allowing MRTF to translocate into the nucleus and together with SRF (serum response factor) drive the SMA (smooth muscle actin) promoter, thus promoting both hypertrophy and hyperplasia in parallel. P = phosphorylated; PAH = pulmonary arterial hypertension.
The recognition of SMAD3 expression levels as an important master switch in the pathogenesis of PAH not only identifies loss of SMAD3 as new cellular pathomechanism of lung vascular remodeling but also constitutes, in our view, an important conceptual advance, in that the concurrent stimulation of proliferative and hypertrophic signaling pathways reconciles the seemingly mutually exclusive, parallel induction of a synthetic and contractile huPASMC phenotype and recognizes MRTF signaling as a double-edged sword that maintains BMP-regulated vascular homeostasis in the healthy lung, while similarly driving TGF-b induced lung vascular remodeling in PAH. n Author disclosures are available with the text of this article at www.atsjournals.org.
